Imatinib Devatis (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic malignancies and select solid tumors.

• Chronic myeloid leukemia (CML): reduces disease burden by targeting BCR‑ABL‑positive leukemic cells, leading to hematologic and cytogenetic responses and can achieve long‑term molecular remission in many patients.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates by inhibiting the BCR‑ABL fusion protein that drives leukemic proliferation and contributes to durable molecular responses.
• Gastrointestinal stromal tumor (GIST): controls tumor growth by blocking c‑KIT and PDGFR signaling pathways in KIT‑mutated tumors, providing disease stabilization in advanced cases.

• Imatinib selectively inhibits the intracellular tyrosine kinases BCR‑ABL, c‑KIT and platelet‑derived growth factor receptor (PDGFR). By binding to the ATP‑binding pocket of these enzymes, it prevents phosphorylation of downstream substrates, thereby blocking proliferative and survival signaling pathways in malignant cells that depend on these kinases. This targeted inhibition reduces uncontrolled cell growth and induces apoptosis in affected tissues.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of hands, feet, or face.
• Muscle cramps or pain: often in the limbs.
• Fatigue: generalized tiredness.

Serious or Rare Side Effects

• Neutropenia: significant reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Cardiac dysfunction: including heart failure or reduced ejection fraction.

When prescribing Imatinib, clinicians should consider several safety precautions.

• Monitor blood counts: regular CBC to detect cytopenias.
• Assess liver function: periodic LFTs for hepatotoxicity.
• Evaluate cardiac status: baseline and follow‑up echocardiograms in at‑risk patients.
• Pregnancy risk: contraindicated in pregnancy due to fetal toxicity; use effective contraception.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Imatinib interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Imatinib plasma levels.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Imatinib exposure, requiring dose adjustment.
• Warfarin: may enhance anticoagulant effect, necessitating INR monitoring.
• Proton pump inhibitors: may modestly reduce absorption; separate dosing times.